UFP Technologies is executing a strategic pivot toward higher-margin medical devices, with revenue growth accelerating to 15.1% in Q2 2026 and gross margins holding near 29.3%. The balance sheet has strengthened considerably, with debt-to-equity falling from 0...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $2.69+16.5% vs $2.31 | $174M+9.1% vs $159M |
Q2 2026 May 4, 2026 | $2.27+4.1% vs $2.18 | $154M-0.4% vs $155M |
Q1 2026 Feb 24, 2026 | $2.44+8.0% vs $2.26 | $149M-0.1% vs $149M |
Q4 2025 Nov 3, 2025 | $2.39+7.7% vs $2.22 | $155M+3.7% vs $149M |
California State Teachers Retirement System boosted its stake in shares of UFP Technologies, Inc. (NASDAQ: UFPT) by 25,730.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,366,550 shares of the industrial products company's stock after purchasing an additional 2,357,388
Investors need to pay close attention to UFPT stock based on the movements in the options market lately.
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
The sale represents a total value of $324,260. The disposition was executed entirely through direct ownership, leaving the insider with 4,476 shares held directly.
Benchmark UFPT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for UFP Technologies, Inc. (UFPT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $287.38 | $2.22B | 32.77 | 19.5% | 11.33% | 17.82% | — | |
| $105.80 | $1.25B | 10.16 | -0.2% | 46.36% | 17.32% | — | |
| $12.31 | $1.05B | 24.46 | 7.02% | 9.47% | 16.38% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $3.86 | $203.09M | -3.61 | -9.06% | -7.15% | -22.07% | — | |
| $67.33 | $4.1B | 18.10 | 3.71% | 5.75% | 7.51% | — |
UFP Technologies, Inc. (UFPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
UFP Technologies, Inc. (UFPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 10, 2026·SEC
Jun 8, 2026·SEC
Get notified when UFPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
UFP Technologies, Inc. (UFPT) stock FAQ — growth, dividends, profitability & financials explained
UFP Technologies, Inc. (UFPT) reported $631.6M in revenue for fiscal year 2025. This represents a 1503% increase from $39.4M in 1996.
UFP Technologies, Inc. (UFPT) grew revenue by 19.5% over the past year. This is strong growth.
Yes, UFP Technologies, Inc. (UFPT) is profitable, generating $72.3M in net income for fiscal year 2025 (11.3% net margin).
UFP Technologies, Inc. (UFPT) has a return on equity (ROE) of 17.8%. This is reasonable for most industries.
UFP Technologies, Inc. (UFPT) generated $61.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
